Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-02-28 @ 2:28 PM
Study NCT ID:
NCT00782093
Status:
COMPLETED
Last Update Posted:
2024-02-21
First Post:
2008-10-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Sponsor:
Ophthotech Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-10
Start Date Type:
None
Primary Completion Date:
2012-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-06
Completion Date Type:
ACTUAL
First Submit Date:
2008-10-29
First Submit QC Date:
None
Study First Post Date:
2008-10-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-20
Last Update Post Date:
2024-02-21
Last Update Post Date Type:
ACTUAL